Banco Bilbao Vizcaya Argentaria S.A. Sells 2,418 Shares of Biogen Inc. (NASDAQ:BIIB)

Banco Bilbao Vizcaya Argentaria S.A. lessened its holdings in Biogen Inc. (NASDAQ:BIIB - Free Report) by 1.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 127,282 shares of the biotechnology company's stock after selling 2,418 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A. owned approximately 0.09% of Biogen worth $19,445,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Larson Financial Group LLC boosted its stake in Biogen by 640.9% in the fourth quarter. Larson Financial Group LLC now owns 163 shares of the biotechnology company's stock valued at $25,000 after acquiring an additional 141 shares during the last quarter. Lee Danner & Bass Inc. acquired a new position in shares of Biogen in the 4th quarter valued at $25,000. OFI Invest Asset Management bought a new position in shares of Biogen in the 4th quarter worth $32,000. SRS Capital Advisors Inc. acquired a new stake in shares of Biogen during the fourth quarter worth $33,000. Finally, Golden State Wealth Management LLC bought a new stake in Biogen in the fourth quarter valued at about $41,000. Institutional investors and hedge funds own 87.93% of the company's stock.

Insider Buying and Selling

In other news, Director Stephen A. Sherwin sold 8,760 shares of Biogen stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $150.02, for a total transaction of $1,314,175.20. Following the completion of the transaction, the director now directly owns 11,318 shares in the company, valued at approximately $1,697,926.36. The trade was a 43.63 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.16% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Scotiabank decreased their target price on Biogen from $244.00 to $224.00 and set a "sector outperform" rating for the company in a research report on Thursday, February 13th. Wells Fargo & Company decreased their price objective on shares of Biogen from $165.00 to $140.00 and set an "equal weight" rating for the company in a report on Thursday, February 13th. Citigroup cut their target price on shares of Biogen from $160.00 to $145.00 and set a "neutral" rating on the stock in a report on Thursday, February 13th. Sanford C. Bernstein started coverage on shares of Biogen in a research report on Tuesday, February 11th. They set a "market perform" rating and a $160.00 price target on the stock. Finally, Royal Bank of Canada upped their price objective on shares of Biogen from $221.00 to $225.00 and gave the company an "outperform" rating in a research report on Tuesday, April 22nd. Eighteen analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $211.37.

Biogen Stock Down 0.6 %

Shares of NASDAQ:BIIB traded down $0.67 during midday trading on Friday, hitting $118.84. The stock had a trading volume of 1,538,299 shares, compared to its average volume of 1,350,289. The company has a market cap of $17.40 billion, a P/E ratio of 10.62, a PEG ratio of 1.51 and a beta of 0.06. Biogen Inc. has a 12 month low of $110.04 and a 12 month high of $238.00. The business's 50-day simple moving average is $132.47 and its 200-day simple moving average is $149.14. The company has a quick ratio of 0.90, a current ratio of 1.35 and a debt-to-equity ratio of 0.27.

Biogen (NASDAQ:BIIB - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 EPS for the quarter, beating analysts' consensus estimates of $3.43 by $0.01. Biogen had a net margin of 16.87% and a return on equity of 14.98%. On average, sell-side analysts forecast that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

Biogen Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.